Faculty Bibliography
Searched for:
in-biosketch:true
person:kruppl01
Total Results:
629
VIRAL AND GENETIC RISK FACTORS FOR PEDIATRIC NEUROMYELITIS OPTICA [Meeting Abstract]
ISI:000323709300042
ISSN: 1352-4585
CID: 2154292
Child neuropsychology : a journal on normal & abnormal development in childhood & adolescence. 2013:19(1):1-22.DOI: 10.1080/09297049.2011.639758
Pediatric Multiple Sclerosis: What we know and where are we headed?
Multiple Sclerosis (MS), an autoimmune mediated disease of the central nervous system, has historically been considered a disease of young adulthood. However, there has been increasing recognition that the disease can occur in adolescence and even early childhood and recent years have witnessed a surge of studies documenting the clinical features of the disease as it pertains to this young population. The purpose of this article is to review the literature on MS in childhood and adolescence, including the clinical presentation of the disease in this group, neuropathology and pathogenesis, magnetic resonance imaging findings, as well as neuropsychological and psychosocial considerations.
PMID: 22375830
ISSN: 0929-7049
CID: 203792
Risk Factors for Transverse Myelitis Compared with Multiple Sclerosis, Neuromyelitis Optica, and Other Neurologic Disorders in Pediatric Patients [Meeting Abstract]
ISI:000332068601185
ISSN: 1526-632x
CID: 2154342
Environmental Risk Factors Associated with Pediatric Neuromyelitis Optica [Meeting Abstract]
ISI:000332068601221
ISSN: 1526-632x
CID: 2154352
Parainfectious meningo-encephalo-radiculo-myelitis (cat scratch disease, Lyme borreliosis, brucellosis, botulism, legionellosis, pertussis, mycoplasma)
Parainfectious disorders of the nervous system encompass those meningo-encephalo-radiculomyelitic conditions that are temporally associated with a systemic infection, antigenic stimuli, or toxin exposure, in the absence of evidence of direct neuronal infection or invasion of the central nervous system (CNS) or peripheral nervous system (PNS). Pathogenetic mechanisms can be due to immune-mediated processes (such as bystander activation, molecular mimicy) or the inciting insult can be due to toxic factors, as in the case of botulism. A myriad of clinical manifestations can occur including headache, seizures, and mental status changes, ranging from mood and behavioral disturbances to varying levels of alteration in consciousness. Focal neurological deficits can include aphasia, hemiparesis, or paraparesis. The PNS can also be affected leading to cranial nerve involvement, focal or multifocal neuropathies, and dysfunction of the autonomic nervous system. Diagnosis is based not only on the history, examination, laboratory, and neuroimaging data but also on epidemiological factors. The parainfectious disorders covered in this review are cat scratch disease, Lyme borreliosis, legionellosis, brucellosis, botulism, pertussis, and mycoplasma. Each is associated with a distinct organism, has both systemic and neurological manifestations, and has a different epidemiological profile.
PMID: 23622329
ISSN: 0072-9752
CID: 1682602
Outcomes following an initial episode of paediatric acute disseminated encephalomyelitis: a retrospective analysis of 65 children from a US network [Meeting Abstract]
ISI:000328751401042
ISSN: 1477-0970
CID: 2234302
Neuro-Behcets Disease; a Case Study [Meeting Abstract]
ISI:000332068604291
ISSN: 1526-632x
CID: 2225752
Subcutaneous Interferon beta-1a in Children and Adolescents with Multiple Sclerosis: Regional Differences in Outcomes and Treatment Patterns in the International REPLAY Study [Meeting Abstract]
ISI:000332068606201
ISSN: 1526-632x
CID: 2225762
Impaired Cognition without Behavioral Problems in Pediatric Clinically Isolated Syndrome (CIS) [Meeting Abstract]
ISI:000332068601177
ISSN: 1526-632x
CID: 2154422
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis
BACKGROUND:BG-12 (dimethyl fumarate) is in development as an oral treatment for relapsing-remitting multiple sclerosis, which is commonly treated with parenteral agents (interferon or glatiramer acetate). METHODS:In this phase 3, randomized study, we investigated the efficacy and safety of oral BG-12, at a dose of 240 mg two or three times daily, as compared with placebo in patients with relapsing-remitting multiple sclerosis. An active agent, glatiramer acetate, was also included as a reference comparator. The primary end point was the annualized relapse rate over a period of 2 years. The study was not designed to test the superiority or noninferiority of BG-12 versus glatiramer acetate. RESULTS:At 2 years, the annualized relapse rate was significantly lower with twice-daily BG-12 (0.22), thrice-daily BG-12 (0.20), and glatiramer acetate (0.29) than with placebo (0.40) (relative reductions: twice-daily BG-12, 44%, P<0.001; thrice-daily BG-12, 51%, P<0.001; glatiramer acetate, 29%, P=0.01). Reductions in disability progression with twice-daily BG-12, thrice-daily BG-12, and glatiramer acetate versus placebo (21%, 24%, and 7%, respectively) were not significant. As compared with placebo, twice-daily BG-12, thrice-daily BG-12, and glatiramer acetate significantly reduced the numbers of new or enlarging T(2)-weighted hyperintense lesions (all P<0.001) and new T(1)-weighted hypointense lesions (P<0.001, P<0.001, and P=0.002, respectively). In post hoc comparisons of BG-12 versus glatiramer acetate, differences were not significant except for the annualized relapse rate (thrice-daily BG-12), new or enlarging T(2)-weighted hyperintense lesions (both BG-12 doses), and new T(1)-weighted hypointense lesions (thrice-daily BG-12) (nominal P<0.05 for each comparison). Adverse events occurring at a higher incidence with an active treatment than with placebo included flushing and gastrointestinal events (with BG-12) and injection-related events (with glatiramer acetate). There were no malignant neoplasms or opportunistic infections reported with BG-12. Lymphocyte counts decreased with BG-12. CONCLUSIONS:In patients with relapsing-remitting multiple sclerosis, BG-12 (at both doses) and glatiramer acetate significantly reduced relapse rates and improved neuroradiologic outcomes relative to placebo. (Funded by Biogen Idec; CONFIRM ClinicalTrials.gov number, NCT00451451.).
PMID: 22992072
ISSN: 1533-4406
CID: 5347972
